FDA Approves ZORYVE Cream 0.3% for Plaque Psoriasis in Children as Young as 2 (ARQT)

FDA Approval

The FDA has approved ZORYVE cream 0.3% for the treatment of plaque psoriasis in children as young as 2 years old, according to an announcement from Arcutis Biotherapeutics (NASDAQ: ARQT). The approval makes ZORYVE cream 0.3% the first once-daily, non-steroidal therapy cleared for this indication in pediatric patients in that age group. Shares of ARQT fell 2.02% on Tuesday, June 30, 2026, closing at $26.22.

What Changed

• First-in-class designation: ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for plaque psoriasis in patients as young as 2 years of age, per the company's announcement.
• Steroid-free profile: The therapy offers a non-steroidal treatment option, a clinically meaningful distinction for pediatric patients where long-term corticosteroid use carries known safety considerations.
• Tolerability profile: According to Arcutis, ZORYVE cream 0.3% was found to be safe, effective, and well-tolerated for use anywhere on the body in this patient population.
• Label expansion: This approval extends the existing ZORYVE cream franchise to a new and younger patient segment, broadening the addressable population for the product.

Why It Matters

Pediatric plaque psoriasis represents an underserved niche within dermatology, with limited approved non-steroidal options for very young patients. By securing the first once-daily, steroid-free label in children aged 2 and older, Arcutis positions ZORYVE cream 0.3% as a differentiated option in a space where dermatologists have historically faced a narrow toolkit for this age group, according to the company's announcement.

The label expansion also complements a broader commercial push at Arcutis. Supplementary coverage from Stock Titan noted that the company has launched a virtual dermatology platform targeting care gaps for approximately 45 million Americans, suggesting the pediatric ZORYVE approval arrives alongside an expanding access strategy. The combination of a new approved indication and a virtual care infrastructure could support utilization of ZORYVE across both adult and pediatric patient populations.

Wall Street View

Wall Street remains constructive on Arcutis heading into this regulatory milestone. As of June 1, 2026, analyst consensus stood at 4 Strong Buy, 8 Buy, and 2 Hold ratings, with no Sell or Strong Sell recommendations, unchanged from the prior month's distribution. The company carries a forward P/E of 22.7x against a revenue growth rate of 60.1% year-over-year and a gross margin of 90.9% on a trailing basis, reflecting the high-margin profile typical of a specialty pharmaceutical franchise.

Investor Takeaway

The FDA's clearance of ZORYVE cream 0.3% for patients as young as 2 years old adds a first-mover, steroid-free label in pediatric plaque psoriasis to Arcutis' commercial portfolio, a distinction that could support prescriber adoption in an age group with few approved alternatives. With a 14-analyst consensus skewed heavily toward Buy and Strong Buy as of June 1, 2026, the Street appears to view the ZORYVE franchise as a durable growth driver. Whether the pediatric label translates into a meaningful revenue contribution will depend on uptake rates that have yet to be publicly disclosed.